Related Experiment Video
Updated: Jul 2, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Drugs treatment of pain in multiple sclerosis
Antonio Siniscalchi1, Luca Gallelli, Giovambattista De Sarro
1Department of Neuroscience, Neurology Division, Annuziata Hospital, Cosenza, Italy.
Abstract:
Pain is a frequent and disabling symptom among multiple sclerosis (MS) and it is estimated to occur in 55% to 65% of patients. The mechanism of pain in MS has not yet been defined, because it can result from somatic, visceral, emotional, or neurologic impairment. The importance of this classification is related to different medical approaches to treat the pain in MS patients. In the management of symptomatic pain, new therapeutic strategies are now available to represent a great opportunity improving the quality of life. The availability of newer drugs for symptomatic treatment of pain in MS indicates a need to pay attention to this problem.
Related Concept Videos
Analgesia and Pain Management
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Multiple Sclerosis l: Introduction
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...

